1. |
Narváez J. Systemic lupus erythematosus 2020. Med Clin (Barc), 2020, 155(11): 494-501.
|
2. |
Parikh SV, Almaani S, Brodsky S, et al. Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis, 2020, 76(2): 265-281.
|
3. |
Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers, 2020, 6(1): 7.
|
4. |
Raimbourg Q, Daugas É. Lupus nephritis. Nephrol Ther, 2019, 15(3): 174-189.
|
5. |
Musaelyan A, Lapin S, Nazarov V, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev, 2018, 17(9): 926-934.
|
6. |
Sharma P, Alsharif S, Fallatah A, et al. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. Cells, 2019, 8(5): 497.
|
7. |
Strouhalova K, Přechová M, Gandalovičová A, et al. Vimentin intermediate filaments as potential target for cancer treatment. Cancers (Basel), 2020, 12(1): 184.
|
8. |
Fuchs E, Weber K. Intermediate filaments: structure, dynamics, function, and disease. Annu Rev Biochem, 1994, 63: 345-382.
|
9. |
Goldie KN, Wedig T, Mitra AK, et al. Dissecting the 3-D structure of vimentin intermediate filaments by cryo-electron tomography. J Struct Biol, 2007, 158(3): 378-385.
|
10. |
Dave JM, Bayless KJ. Vimentin as an integral regulator of cell adhesion and endothelial sprouting. Microcirculation, 2014, 21(4): 333-344.
|
11. |
Ivaska J, Pallari HM, Nevo J, et al. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res, 2007, 313(10): 2050-2062.
|
12. |
Battaglia RA, Delic S, Herrmann H, et al. Vimentin on the move: new developments in cell migration. F1000Res, 2018, 7: F1000 Faculty Rev-1796.
|
13. |
李国炜, 李海洋. 波形蛋白的生物学功能及相关病理的研究进展. 医学综述, 2018, 24(7): 1273-1278.
|
14. |
Patteson AE, Vahabikashi A, Goldman RD, et al. Mechanical and non-mechanical functions of filamentous and non-filamentous vimentin. Bioessays, 2020, 42(11): e2000078.
|
15. |
Danielsson F, Peterson MK, Caldeira Araújo H, et al. Vimentin diversity in health and disease. Cells, 2018, 7(10): 147.
|
16. |
Ebrahimi-Rad M, Khatami S, Akhbari H, et al. Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients. Reumatologia, 2020, 58(6): 350-356.
|
17. |
Kinloch AJ, Kaiser Y, Wolfgeher D, et al. In situ humoral immunity to vimentin in HLA-DRB1*03+ patients with pulmonary sarcoidosis. Front Immunol, 2018, 9: 1516.
|
18. |
Alessandri C, Agmon-Levin N, Conti F, et al. Anti-mutated citrullinated vimentin antibodies in antiphospholipid syndrome: diagnostic value and relationship with clinical features. Immunol Res, 2017, 65(2): 524-531.
|
19. |
Mortensen JH, van Haaften WT, Karsdal MA, et al. The citrullinated and MMP-degraded vimentin biomarker (VICM) predicts early response to anti-TNFα treatment in Crohn’s disease. J Clin Gastroenterol, 2021, 55(1): 59-66.
|
20. |
Surolia R, Li FJ, Wang Z, et al. Vimentin intermediate filament assembly regulates fibroblast invasion in fibrogenic lung injury. JCI Insight, 2019, 4(7): e123253.
|
21. |
Divanyan T, Acosta E, Patel D, et al. Anti-vimentin antibodies in transplant and disease. Hum Immunol, 2019, 80(8): 602-607.
|
22. |
Broder A, Mowrey WB, Khan HN, et al. Tubulointerstitial damage predicts end stage renal disease in lupus nephritis with preserved to moderately impaired renal function: a retrospective cohort study. Semin Arthritis Rheum, 2018, 47(4): 545-551.
|
23. |
Clark MR, Trotter K, Chang A. The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol, 2015, 35(5): 455-464.
|
24. |
Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol, 2011, 186(3): 1849-1860.
|
25. |
Winchester R, Wiesendanger M, Zhang HZ, et al. Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8+ T cell β-chain clonotypes in progressive lupus nephritis. Arthritis Rheum, 2012, 64(5): 1589-600.
|
26. |
Kinloch AJ, Chang A, Ko K, et al. Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis. Arthritis Rheumatol, 2014, 66(12): 3359-3370.
|
27. |
Goilav B, Putterman C. The role of anti-DNA antibodies in the development of lupus nephritis: a complementary, or alternative, viewpoint?. Semin Nephrol, 2015, 35(5): 439-443.
|
28. |
André-Schwartz J, Datta SK, Shoenfeld Y, et al. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. Clin Immunol Immunopathol, 1984, 31(2): 261-271.
|
29. |
Bruschi M, Sinico RA, Moroni G, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol, 2014, 25(11): 2483-2498.
|
30. |
Fragiadaki M, Mason RM. Epithelial-mesenchymal transition in renal fibrosis - evidence for and against. Int J Exp Pathol, 2011, 92(3): 143-150.
|
31. |
Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol, 2011, 7(12): 684-696.
|
32. |
Cao YH, Lv LL, Zhang X, et al. Urinary vimentin mRNA as a potential novel biomarker of renal fibrosis. Am J Physiol Renal Physiol, 2015, 309(6): F514-F522.
|
33. |
Galichon P, Hertig A. Epithelial to mesenchymal transition as a biomarker in renal fibrosis: are we ready for the bedside?. Fibrogenesis Tissue Repair, 2011, 4: 11.
|
34. |
Muchaneta-Kubara EC, el Nahas AM. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol Dial Transplant, 1997, 12(5): 904-915.
|
35. |
Bob FR, Gluhovschi G, Herman D, et al. Histological, immunohistochemical and biological data in assessing interstitial fibrosis in patients with chronic glomerulonephritis. Acta Histochem, 2008, 110(3): 196-203.
|
36. |
Davidson A. Editorial: autoimmunity to vimentin and lupus nephritis. Arthritis Rheumatol, 2014, 66(12): 3251-3254.
|
37. |
Rocha LP, Xavier SC, Helmo FR, et al. Epithelial-mesenchymal transition in pediatric nephropathies. Pathol Res Pract, 2016, 212(12): 1157-1166.
|
38. |
王艳, 王德琴, 缪娴静. 系统性红斑狼疮肾炎患者中波形蛋白的水平变化及临床意义. 临床肾脏病杂志, 2019, 19(8): 618-620.
|
39. |
Li Y, Jia R, Liu Y, et al. Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus, 2020, 29(3): 239-247.
|
40. |
Kinloch AJ, Cascino MD, Dai J, et al. Anti-vimentin antibodies: a unique antibody class associated with therapy-resistant lupus nephritis. Lupus, 2020, 29(6): 569-577.
|
41. |
Anania VG, Yu K, Pingitore F, et al. Discovery and qualification of candidate urinary biomarkers of disease activity in lupus nephritis. J Proteome Res, 2019, 18(3): 1264-1277.
|